Skip to main content

About your Search

20121001
20121009
Search Results 0 to 2 of about 3
are taking risks. >> oh, sure, in this environment, i mean, you know, we're watching liquidity like a hawk because there's great sense tomorrow morning it could go the other way, in effect you don't invest as much, you don't take as much risk. >> how would you counter the argument that businesspeople and the wealthy have had their way for the past 2030-years as they've increased their lead in terms of income disparity and gotten richer and richer, and you would have hoped that some of that would have trickled down, if it works you would have hoped the average person would have participated in the good times and haven't and you need a president that is going to come in for the powerless people that aren't able to set policy and pay to go do things and you need someone that will represent them in the future. how was is that pretty damned good? >> yes, sir. >> you can take this. thank you for writing it for me. >> i'll get you a job at "the new york times." the reality is as follows. the whole focus has been on how the quote, one percenters or ten percenters, how the top earners moved ahead o
earnings are not correlated with the macro environment. ubs writes that alexion is a significant double-digit growth driver but uses the orphan drug model where pricing and reimbursement are insulated, the biotech is up a whopping 400% over the past three years. keep in mind this is a speculative takeout target. another standout stock, gilead sciences is up 70% year-to-date, ubs has it as its top large tech biotech pick, it's attractively trading to a discount to the biotech sector, biogen up 50% in the past year thanks to its strong earnings performance and anticipation riding behind its multiple sclerosis drug bg12 which could get approval by year's end. another is buyout speculation. the firms are on the hunt for under the radar biotech firms, bristol-myers among others making big bets. andrew you've been following that as well. >> thank you for that report. lot of beta. see if there's any alpha. >>> in the next hour of "squawk box" former ubs american chairman robert wolf will join us to talk financials, jobs and the election, mr. obama's favorite banker. and later health care, a ma
, basically small businesses are just not growing in this environment and big businesses are chasing profits abroad. so the government is just not getting the tax take on that front. in the asset classes, you can see some of the levels not that good at the moment. bundes still attracting a lot of attention. we've been waiting on spain to fishlgly l-- officially ask fo that aid. nonetheless, we're not seeing too much pressure on the periphery, 5.75%. let me send it back to you. >> thank you very much. the first presidential debate. john harwood is on the ground in denver. he joins us with the latest nbc news "wall street journal" poll. it looks like things are starting to even out at least a little. is this the bounce that president obama got after the democratic convention coming back down? >> well, i think it's the bounce from the convention and the surge that he got on top of the convention with that 47% video, so there is some good news for romney. not only our national poll, but also in the swing state polls that we do with "the wall street journal" and maris college. take a look at the
Search Results 0 to 2 of about 3